Literature DB >> 12406040

Impact of weight loss on the metabolic syndrome.

C C Case1, P H Jones, K Nelson, E O'Brian Smith, C M Ballantyne.   

Abstract

AIM: Individuals with the metabolic syndrome (MS), a clustering of risk factors [triglycerides, glucose, high-density lipoprotein cholesterol, blood pressure (BP), abdominal obesity] defined by the National Cholesterol Education Program (NCEP), are at high risk for coronary heart disease and type 2 diabetes mellitus, and may benefit from aggressive lifestyle modification.
METHODS: We reviewed 1 year of consecutive patients' charts to determine the prevalence of the MS in obese individuals enrolled in a medically supervised rapid weight loss programme, the correlation of weight change with the components of the MS, and response to diet-induced weight loss.
RESULTS: Out of 185 individuals, 125 (68%) met the NCEP definition of the MS. A moderate decrease in weight (6.5%) induced by a very low calorie diet (VLCD) resulted in substantial reductions of systolic (11.1 mmHg) and diastolic (5.8 mmHg) blood pressure (BP), glucose (17 mg/dl), triglycerides (94 mg/dl) and total cholesterol (37 mg/dl) at 4 weeks (all p < 0.001). These improvements were sustained at the end of active weight loss (average 16.7 weeks; total weight loss 15.1%), with further significant reductions in BP and triglycerides. Weight loss was related to the changes in each criterion of the metabolic syndrome.
CONCLUSIONS: The MS is prevalent in two-thirds of obese individuals enrolling in a structured weight loss programme. Moderate weight loss with a VLCD markedly improved all aspects of the MS.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12406040     DOI: 10.1046/j.1463-1326.2002.00236.x

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  48 in total

1.  Effect of long-term whole body vibration training on visceral adipose tissue: a preliminary report.

Authors:  Dirk Vissers; An Verrijken; Ilse Mertens; Caroline Van Gils; Annemie Van de Sompel; Steven Truijen; Luc Van Gaal
Journal:  Obes Facts       Date:  2010-04-07       Impact factor: 3.942

2.  Laparoscopic Roux-en-Y versus mini-gastric bypass for the treatment of morbid obesity: a prospective randomized controlled clinical trial.

Authors:  Wei-Jei Lee; Po-Jui Yu; Weu Wang; Tai-Chi Chen; Po-Li Wei; Ming-Te Huang
Journal:  Ann Surg       Date:  2005-07       Impact factor: 12.969

3.  Weight change and changes in the metabolic syndrome as the French population moves towards overweight: the D.E.S.I.R. cohort.

Authors:  T A Hillier; A Fagot-Campagna; E Eschwège; S Vol; M Cailleau; B Balkau
Journal:  Int J Epidemiol       Date:  2005-12-22       Impact factor: 7.196

4.  Genes involved in obesity: Adipocytes, brain and microflora.

Authors:  L Macia; O Viltart; C Verwaerde; M Delacre; A Delanoye; C Grangette; I Wolowczuk
Journal:  Genes Nutr       Date:  2006-09       Impact factor: 5.523

Review 5.  Impact of metabolic syndrome on cognition and brain: a selected review of the literature.

Authors:  Kathy F Yates; Victoria Sweat; Po Lai Yau; Michael M Turchiano; Antonio Convit
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-09       Impact factor: 8.311

6.  Does metabolic syndrome mitigate weight loss in overweight Mexican American women treated for 1-year with orlistat and lifestyle modification?

Authors:  M M Pinkston; W S C Poston; R S Reeves; C K Haddock; J E Taylor; J P Foreyt
Journal:  Eat Weight Disord       Date:  2006-03       Impact factor: 4.652

7.  Circulating markers of inflammation and their link to indices of adiposity.

Authors:  Lucy M Browning; Jeremy D Krebs; Edel C Magee; Gema Frühbeck; Susan A Jebb
Journal:  Obes Facts       Date:  2008-10-23       Impact factor: 3.942

8.  Weight change and incident metabolic syndrome in Iranian men and women; a 3 year follow-up study.

Authors:  Azadeh Zabetian; Farzad Hadaegh; Parvin Sarbakhsh; Fereidoun Azizi
Journal:  BMC Public Health       Date:  2009-05-13       Impact factor: 3.295

9.  Weight change over five-year periods and number of components of the metabolic syndrome in a Dutch cohort.

Authors:  M Bot; A M W Spijkerman; J W R Twisk; W M M Verschuren
Journal:  Eur J Epidemiol       Date:  2010-01-21       Impact factor: 8.082

10.  DASH lowers blood pressure in obese hypertensives beyond potassium, magnesium and fibre.

Authors:  Y Al-Solaiman; A Jesri; W K Mountford; D T Lackland; Y Zhao; B M Egan
Journal:  J Hum Hypertens       Date:  2009-07-23       Impact factor: 3.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.